KRAS and colorectal carcinoma: Reovirus treatment, which uses unmodified reovirus to attack the cancer cells, is being considered as an additional treatment, especially for patients with KRAS-mutated CRC who are currently considered ineligible to receive epidermal growth factor receptor (EGFR) directed therapy due to resistance and potentially detrimental outcomes [7].